TMC Pharma appoints Gordon Cameron to board


Share post:

Orphan Drug development specialist TMC Pharma has appointed Gordon Cameron to its board as a non-executive director.

Mr Cameron has 25 years’ board-level experience in biotech and pharmaceutical services sectors. He started his career with EY, then spent several years in investment banking at Rothschild before becoming CFO, and then CEO, of international vaccine company Acambis.

For the past 15 years, Mr Cameron has been CFO of Quotient Sciences, an international Contract Development and Manufacturing Organization and Clinical Research Organization.

In 2004, he was awarded the Officer of the Order of the British Empire for services to the British biotechnology industry.

Julie Matthews, chief executive officer of TMC Pharma, said that the new appointment would “enhance our strategic capability and tactical execution as we consolidate our position as a global leader in the Orphan Drug development market.”

Mr Cameron, added: “TMC Pharma has established itself as a significant player in a fast-growing segment of the global pharmaceutical industry. I am excited to join its board and support Julie and the team as they continue to expand in the UK and the rest of the world.”

Also ReadMichael Scott and Charlotte Skitterall recognised in the New Year Honours list 2023


Please enter your comment!
Please enter your name here

Current Issue June 2023

Related articles

MHRA grants authorisation for LEO Pharma’s Adtralza 2 mL pen solution

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution...

Grundon launches maiden UK-wide inhaler recycling programme

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and...

‘Record fine imposed on hydrocortisone manufacturers for dominant position abuse and 10,000% price increase’

The Competition Appeal Tribunal (CAT) has upheld the Competition and Markets Authority’s (CMA) findings against two pharmaceutical manufacturers...

Vision Report: Legal reforms, adequate funding imperative for success of community pharmacy

Achieving the community pharmacy vision necessitates legal adjustments and additional funding beyond recent boosts, the pharmacy vision document...